Piper Sandler analyst Adam Maeder reiterates an Overweight rating with an $8 price target on Neuronetics saying the company reported a "nice Q4 beat across-the-board." The company saw "strong sequential uptick" in both Neurostar system sales and session revenue throughout the quarter, and this momentum is likely to prove durable in the coming years, Maeder tells investors in a research note. The analyst continues to view Neuronetics as a mid-teens sales grower looking out into 2023 and beyond. He says Neuronetics is an "attractive small-cap medtech story."
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on STIM:
- Neuronetics Settles Litigation Against BrainsWay
- Neuronetics sees Q4 revenue $18M, consensus $16.54M
- Neuronetics Reports Preliminary Fourth Quarter and Fiscal Year 2022 Financial Results
- Neuronetics Announces Appointment of Joseph H. Capper to its Board of Directors
- Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)